title: Treatment of early epithelial ovarian cancer with chemotherapy and abdominopelvic radiotherapy: results of a prospective treatment protocol.
abstract: OBJECTIVE
  To test the hypothesis that the combination of adjuvant chemotherapy and abdominopelvic radiation (APRT) improves the outcome of patients with early ovarian cancer compared to treatment with APRT alone.
  
  
  METHODS
  Between 1991 and 1994, 93 patients with Stage I to III, optimally cytoreduced, invasive, epithelial ovarian cancer were treated with sequential chemotherapy and APRT. Treatment was assigned using a prognostic classification that was derived from previous cohorts of patients. Low-risk patients (n = 9) received APRT alone, intermediate-risk patients (n = 66) received two courses of cisplatin followed by APRT, and high-risk patients (n = 18) received 6 courses of cisplatin and cyclophosphamide followed by APRT.
  
  
  RESULTS
  Disease recurred in 22 patients, and was confined to the pelvis or abdomen in 15. Nine patients died and the remainder were alive with disease after receiving salvage chemotherapy. The 3-year disease-free and overall survivals were 78% and 91%, respectively. The prognostic classification used to assign treatment was the only factor that predicted disease-free survival (83% and 59% at 3 years for low/intermediate- and high-risk patients, respectively; p = 0.03). There was no detectable difference in outcome between the present series and an historical control group treated with APRT alone. Treatment was well tolerated and only 2 patients (2.5%) developed serious complications.
  
  
  CONCLUSIONS
  APRT is an effective adjuvant treatment for carefully selected patients with early ovarian cancer. The addition of chemotherapy as used in this study to APRT does not significantly improve outcome compared to APRT alone.
authors.affiliation: Department of Radiation Oncology, Princess Margaret Hospital and the University of Toronto, Ontario, Canada.
authors.forename: R
authors.initials: R
authors.lastname: Wong
authors.forename: M
authors.initials: M
authors.lastname: Milosevic
authors.forename: J
authors.initials: J
authors.lastname: Sturgeon
authors.forename: M
authors.initials: M
authors.lastname: Pintilie
authors.forename: A
authors.initials: A
authors.lastname: Fyles
authors.forename: W
authors.initials: W
authors.lastname: Levin
authors.forename: B
authors.initials: B
authors.lastname: Rosen
authors.forename: D
authors.initials: D
authors.lastname: Depetrillo
authors.forename: A
authors.initials: A
authors.lastname: Oza
authors.forename: L
authors.initials: L
authors.lastname: Manchul
authors.forename: J
authors.initials: J
authors.lastname: Murphy
authors.forename: W
authors.initials: W
authors.lastname: Chapman
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy* / Q000556:secondary; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D011446:Prospective Studies; D018714:Radiotherapy, Adjuvant
chemical_list: D003520:Cyclophosphamide; D002945:Cisplatin